ScreenerHero
GENOGenovis AB (publ.)
STO · SE · Healthcare · Biotechnology · genovis.com
20.10SEK+1.31%Mkt Cap: 129.70M $P/E: 64.84

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOU…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap129.70M $
Enterprise Value119.87M $
Revenue (TTM)13.10M $
Gross Profit11.08M $
Net Income (TTM)2.25M $
Revenue/Share0.1979 USD
Last Price20.10 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002485979
Valuation
P/E (Trailing)64.84
P/E (Forward)42.55
PEG—
EV/EBITDA38.05
EV/Revenue9.15
P/S9.85
P/B4.38
EPS (TTM)0.31
EPS (Forward)0.47
52W Range
15.6444% of range25.85
52W High25.85 SEK
52W Low15.64 SEK
Profitability
Gross Margin89.85%
Oper. Margin9.24%
EBITDA Margin24.04%
Profit Margin18.22%
ROE8.65%
ROA6.22%
Growth
Revenue Growth20.30%
Earnings Growth-74.70%
Cash Flow & Leverage
Operating CF3.06M $
CapEx (TTM)1.20M $
FCF Margin21.99%
FCF Yield2.22%
Net Debt-8.15M $
Net Debt/EBITDA-2.59
Balance Sheet
Debt/Equity0.27
Current Ratio5.76
Quick Ratio4.44
Book Value/Sh4.566 SEK
Cash/Share2.330 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 4, 2012
Analyst Consensus
Rating—
Target (Mean)33.00 SEK
Upside (mean)+64.2%
Target Range28.00 SEK – 38.00 SEK
SEK28.00+64.2% to meanSEK38.00
# Analysts2
Ownership
Shares Out.67.46M
Float56.60M
Insiders16.79%
Institutions37.67%
Technical
SMA 5019.43 (+3.4%)
SMA 20019.58 (+2.7%)
Beta1.72
S&P 52W Chg18.16%
Avg Vol (30d)56.30K
Avg Vol (10d)106.58K
Technical Indicators
RSI (14)53.9
MACD0.0638
MACD Signal0.0538
MACD Hist.+0.0100
BB Upper20.29 SEK
BB Middle19.65 SEK
BB Lower19.00 SEK
BB Width6.57%
ATR (14)0.7730 SEK
Vol Ratio (20d)2.30x